SynthesisPloS one2025

Safety outcomes of statin vs non-statin lipid-lowering interventions in patients with prior statin-associated muscle symptoms: A systematic review and meta-analysis.

What the trial testedas reported · 1,868 people · 2025

Not counted

1.5×1× to 2.1×

Bigger than 7 in 10 for adverse events & safety

As reported

OR 1.48, 95% CI 1.03–2.12

the abstract, start to end

… than the comparator groups (OR 1.48, 95%CI 1.03-2.12, I2 = 17.6%).

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

OR 1.481.03–2.12

StatinsAdverse events & safety

1 / 3